Crestline Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-32,439
| Closed | -$1.23M | – | 242 |
|
|
2022
Q4 | $1.23M | Sell |
32,439
-4,669
| -13% | -$177K | 0.18% | 88 |
|
|
2022
Q3 | $933K | Buy |
37,108
+10,400
| +39% | +$261K | 0.13% | 119 |
|
|
2022
Q2 | $812K | Buy |
26,708
+13,621
| +104% | +$414K | 0.11% | 134 |
|
|
2022
Q1 | $429K | Buy |
+13,087
| New | +$429K | 0.05% | 188 |
|
|
2021
Q4 | – | Sell |
-5,909
| Closed | -$594K | – | 277 |
|
|
2021
Q3 | $594K | Sell |
5,909
-103
| -2% | -$10.4K | 0.06% | 137 |
|
|
2021
Q2 | $851K | Buy |
+6,012
| New | +$851K | 0.07% | 106 |
|
|
2018
Q3 | – | Sell |
-26,439
| Closed | -$925K | – | 243 |
|
|
2018
Q2 | $925K | Sell |
26,439
-62,236
| -70% | -$2.18M | 0.1% | 200 |
|
|
2018
Q1 | $1.82M | Buy |
88,675
+19,769
| +29% | +$406K | 0.23% | 82 |
|
|
2017
Q4 | $1.95M | Buy |
68,906
+8,442
| +14% | +$239K | 0.2% | 42 |
|
|
2017
Q3 | $1.88M | Buy |
+60,464
| New | +$1.88M | 0.26% | 71 |
|